Skip to Content
Søk Menu

ASCO 2019: Maintenance Therapy with PARP Inhibitor Olaparib Delays Progression of BRCA-related Pancreatic Cancer

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relateret indhold

Borderline Ovarian Tumors Increase Risk of Some Non-Ovarian Cancers

/ Susanne Krüger Kjær / Charlotte Gerd Hannibal
Gynekologisk kreftLeukemiLungekreftMelanomPancreaskreft
Wungki Park

First-line treatment of claudin 18.2-positive metastatic pancreatic cancer with zolbetuximab, gemcitabine, and nab-paclitaxel

/ Wungki Park
ASCOGI23Pancreaskreft Play the Video 4:43

Prognostisk løft for pasienter med pancreas cancer

/ Trond Buanes
KreftPancreaskreft

ASCO 2019: Flere interessante opfølgende studier af lungecancer

/ Odd Terje Brustugun
ASCO19Lungekreft Play the Video 3:40

ASCO 2019: The first gene expression analysis of patients with advanced breast cancer treated with ribociclib-containing therapy

/ Yen-Shen Lu
ASCO19Brystkreft Play the Video 9:56

ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer

/ Peter Schmid
ASCO19Brystkreft Play the Video 2:54

ASCO 2019: First-line treatment of patients with HER2-positive metastatic breast cancer – 4 years of long-term follow-up data

/ Sandra Swain
ASCO19Brystkreft Play the Video 3:33

ASCO 2019: Affordable Care Act ensures early diagnosis and treatment of ovarian cancer

/ Anna Jo Smith
ASCO19Gynekologisk kreft Play the Video 8:21

ASCO 2019: Private Insurance and higher regional Incomes predict longer survival for Multiple Myeloma

/ Kamal Chamoun
ASCO19Myelomatose Play the Video 6:19
Back to top